DLL3 and small cell lung carcinoma: Inhibition of DLL3 with rovalpituzumab, a DLL3-targeted antibody-drug conjugate, in recurrent SCLC shows single-agent anti-tumor activity and would be expected to also specifically target CSCs [34].